Possibly, wider use of medications such as SGLT-2 inhibitors and GLP-1 receptor agonists which have been shown to have CV protective effects will result in improvements in CAD burden following 2019 for patients with diabetes, however a longer duration of follow-up will be required to confirm whether the attenuation of severity in CAD is a true finding [26–29]. The gene discussed is GLP1R; the disease is diabetes mellitus.